ArticleGastro hep advances2025
Initial Validation of the Eosinophilic Gastritis and Gastroenteritis Quality of Life Scale.
Article in Gastro hep advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial.The lancet. Gastroenterology & hepatology · 2026Trial
- Eosinophilic gastrointestinal diseases.Nature reviews. Disease primers · 2026Review
- Eosinophils Beyond the Esophagus: A Review of Non-EoE Eosinophilic Gastrointestinal Diseases.Gastroenterology & hepatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Eosinophilic gastrointestinal disorders (EGIDs) are chronic immune-mediated conditions characterized by gastrointestinal symptoms and gut eosinophilia. Health-related quality of life (HRQoL) is an important metric to understand patient outcomes; the only disease-specific measure of HRQoL exists for eosinophilic esophagitis (EoE) patients. Patients with non-EoE EGIDs experience unique symptoms and treatment options and disease burden of these rare disorders is under-recognized and considered significant. We aim to validate a new measure of HRQoL specific for adults with non-EoE EGIDs. Methods: The Eosinophilic Gastritis and Gastroenteritis Quality of Life Scale (EGGE-QOL) is 20-items scale developed from patient qualitative interviews assessing HRQoL over the past month. Adult patients were recruited from an academic setting and patient advocacy groups to complete an online questionnaire. Psychometric assessment of the EGGE-QOL included reliability measures (internal consistency, split-half reliability), criterion validity (exploratory factor analysis), and concurrent validity (correlations with EGID symptoms, anxiety, depression, fatigue, and sleep disturbance). Results: Forty-one participants completed the study. The EGGE-QOL had excellent reliability (>0.90). Exploratory factor analysis identified a single structure with 3 possible items for removal. Concurrent validity was supported by moderate to large correlations with psychological symptoms, fatigue and sleep, and symptom severity, frequency, and duration. The most important symptom that impacts non-EoE EGID HRQoL may be frequent diarrhea. Conclusion: The EGGE-QOL is a reliable and valid measure of HRQoL for adults with non-EoE EGIDs, representing an important step in understanding the experiences of these patients and assessing how these conditions may impact daily function. Additional studies are necessary to confirm these findings in larger, diverse cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.